Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Serratiopeptidase is a proteolytic enzyme originally isolated from the non-pathogenic enterobacterium *Serratia* species strain E-15, which resides in the gut of the silkworm. It is widely utilized as an anti-inflammatory, anti-edemic, and fibrinolytic agent, particularly in the management of post-traumatic and post-operative inflammation. The enzyme works by breaking down fibrin and other proteins associated with inflammation and edema, and it also possesses mucolytic properties that help reduce the viscosity of respiratory secretions. In India, Charan Laboratories markets this enzyme as a branded generic under the name SBZ, targeting indications in musculoskeletal, respiratory, and ophthalmological health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on serratiopeptidase.